PLoS ONE (Jan 2018)

Hippo signaling pathway is altered in Duchenne muscular dystrophy.

  • Gian Luca Vita,
  • Francesca Polito,
  • Rosaria Oteri,
  • Roberto Arrigo,
  • Anna Maria Ciranni,
  • Olimpia Musumeci,
  • Sonia Messina,
  • Carmelo Rodolico,
  • Rosa Maria Di Giorgio,
  • Giuseppe Vita,
  • M'Hammed Aguennouz

DOI
https://doi.org/10.1371/journal.pone.0205514
Journal volume & issue
Vol. 13, no. 10
p. e0205514

Abstract

Read online

Hippo signaling pathway is considered a key regulator of tissue homeostasis, cell proliferation, apoptosis and it is involved in cancer development. In skeletal muscle, YAP, a downstream target of the Hippo pathway, is an important player in myoblast proliferation, atrophy/hypertrophy regulation, and in mechano-trasduction, transferring mechanical signals into transcriptional responses. We studied components of Hippo pathway in muscle specimens from patients with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb-girdle muscular dystrophy type 2A and type 2B and healthy subjects. Only DMD muscles had decreased YAP1 protein expression, increased LATS1/2 kinase activity, low Survivin mRNA expression and high miR-21 expression. In light of our novel results, a schematic model is postulated: low levels of YOD1 caused by increased inhibition by miR-21 lead to an increase of LATS1/2 activity which in turn augments phosphorylation of YAP. Reduced amount of active YAP, which is also a target of increased miR-21, causes decreased nuclear expression of YAP-mediated target genes. Since it is known that YAP has beneficial roles in promoting tissue repair and regeneration after injury so that its activation may be therapeutically useful, our results suggest that some components of Hippo pathway could become novel therapeutic targets for DMD treatment.